Core Viewpoint - HeYue-B (02256) has seen a significant stock price increase of nearly 9% post-earnings, with a cumulative rise of close to 40%, reaching a historical high of 14.65 HKD, driven by strong financial performance and positive market sentiment [1] Financial Performance - For the first half of the year, HeYue reported revenue of 612 million HKD, representing a year-on-year growth of 23% [1] - The company's profit reached 328 million HKD, marking a substantial year-on-year increase of 59% [1] Market Reactions - CICC noted that the company's performance exceeded expectations, primarily due to higher-than-expected income from Merck [1] - Citigroup highlighted that HeYue's current valuation is low, considering the high certainty of its two late-stage candidates, pimicotinib and irpagratinib, and the potential for differentiated innovation pipeline to secure external licensing [1] Future Catalysts - Citigroup anticipates key catalysts for HeYue in 2025 and 2026, focusing on the approval and commercialization of pimicotinib, the release of phase III data for irpagratinib, and updates on other candidates like ABSK043 and ABSK061, along with potential commercial collaborations [1]
港股异动 | 和誉-B(02256)涨近9%再创新高 匹米替尼行权费提振业绩 公司上半年纯利同比增长59%